Diabetic Foot Ulcer Treatment Market Size

Diabetic Foot Ulcer Treatment Market Analysis

The Diabetic Foot Ulcer Treatment Market is expected to register a CAGR of 5.9% over the forecast period.
The COVID-19 pandemic significantly impacted the diabetic foot ulcer treatment market. Certain lockdown restrictions, along with delayed accessibility to healthcare facilities, hampered wound care procedures significantly. Additionally, wound care treatment being recognized as non-essential treatment, postponed during the pandemic. For instance, according to an article published by CutisCareUSA in 2020, it was reported that wound care practice is recognized as a non-essential procedure, and a number of outpatient wound care centers were closed during the pandemic. Also, according to an article published by National Center for Biotechnology Information in August 2022, it was reported that approximately 50% and 70% decrease was observed in the foot clinic visit respectively in Manchester city and Los Angeles after lockdown restrictions. This resulted in limited access to the healthcare settings for diabetic foot ulcer treatment procedures and hindered the demand and adoption of diabetic foot ulcer treatment devices during the pandemic. This alternatively limited the growth of the market during the pandemic. However, in the post-pandemic situation, there is an increase in the adoption of wound care products owing to the reopening of the wound care facilities, ease of lockdown restrictions, and increasing tele-consultancy for wound care.
Further, the increasing prevalence of diabetes among the global population is augmenting the risk of diabetic foot ulcers. For instance, in a journal published by the International Diabetes Federation in 2021, it was reported that an estimated 1 in 10 adults suffered from diabetes in 2021 around the globe. According to a report by International Diabetes Federation in February 2022, it was reported that the prevalence of diabetes among the adult population was around 10.0% in Germany, 8.6% in France, and 14.8% in Spain in 2021. According to a report published by National Health Service in September 2022, it was reported that approximately 60,000 patients in the United Kingdom suffered from diabetic foot ulcers every year. Moreover, according to an article published by ANI Media Pvt Ltd in December 2022, it was reported that an estimated 15% of diabetes patients suffer from diabetic foot ulcers. Thus, the increasing number of patients suffering from diabetic foot ulcers is more likely to increase the demand for treatment options and subsequently fuel market growth.
Moreover, technological advancement by the major players in diabetic foot ulcer treatment further fosters the adoption rate of advanced diabetic foot ulcer treatment devices among healthcare professionals. For instance, in January 2020, BenQ Materials Corporation received pre-marketing authorization from Food and Drug Administration (FDA) for Anscare SIMO Negative Pressure Wound Therapy (NPWT) System. This device overcomes the mobility issue for negative pressure wound therapy seamlessly and fuels the adoption rate among healthcare professionals for chronic wound treatment. Also, in April 2020, Huizhou Foryou Medical Devices Co., Ltd. received premarketing authorization for LUOFUCON PHMB alginate dressing which can be used in the management of several wounds, including trauma wounds, diabetic ulcers, and others. Thus, owing to the introduction of such wound care devices and dressing products, the adoption rate of diabetic foot ulcer treatment is anticipated to increase during the study period and fuel market growth.
However, certain factors, including the high cost of chronic wound care devices for the treatment of diabetic foot ulcers, as well as limited awareness among people in developing countries for the available treatment options for diabetic foot ulcers, are limiting the adoption rate of these devices among the general population.